Fusion protein degradation agent and application

By designing fusion protein degradants, using TRIM21-specific binding sequence and KRAS specific binding sequence, simulate "viral-host immune interaction", induce the degradation of TRIM21 and KRAS in pancreatic cancer cells, activate the immune response, and solve the existing solution The lack of TRIM21 in the treatment of pancreatic cancer in technology has achieved effective inhibition and immune activation of pancreatic cancer.

CN119060199APending Publication Date: 2024-12-03TIANJIN MEDICAL UNIV
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202410709413.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-06-03
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively utilize the potential of TRIM21 protein in pancreatic cancer treatment, especially the targets related to KRAS mutation are difficult to apply, and there is a lack of multiple treatment strategies for high-expression diseases of TRIM21.

Method used

Design a fusion protein degradation agent that contains TRIM21-specific binding sequence and KRAS-specific binding sequence. By mimicking "viral-host immune interaction", it induces degradation of TRIM21 and KRAS in lesion cells and activates antiviral immune responses. Achieve multiple therapeutic effects.

Benefits of technology

This degrading agent can effectively inhibit the proliferation of pancreatic cancer cells, and significantly enhance the therapeutic effect on pancreatic cancer through TRIM21-mediated dual-targeted protein degradation and immune activation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060199A_ABST
    Figure CN119060199A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and relates to a fusion protein degradation agent and application thereof. The fusion protein degradation agent comprises a target protein specific binding sequence, a connector and a TRIM21 specific binding sequence which are sequentially connected, wherein the target protein specific binding sequence is a protein sequence specifically bound with a disease-related target protein; the disease-related target protein is a TRIM21 highly expressed disease-related target protein. According to the present invention, by using the characteristic that the TRIM21 simultaneously has two functions of virus elimination and immune signal transduction activation, the degradation agent capable of activating the TRIM21 is constructed, the virus-host immune interaction is simulated, the dual degradation of the disease-related target protein and the TRIM21 is induced, the TRIM21-mediated natural immune signal channel is opened, the antiviral immune response of the pathological change tissue is induced, and the TRIM 21-mediated disease-related target protein and the TRIM 21-mediated disease-related target protein can be degraded. The treatment effect of the degradation agent is enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a fusion protein degrader, DNA and mRNA encoding the degrader, and applications of the same in preparing medicines. Background Art

[0002] With the continuous improvement of people's living standards and the development of biotechnology, people's understanding of diseases and their emphasis on health are also increasing. New drugs and treatment plans are constantly emerging, which often come from new understanding of mechanisms and new designs based on this understanding.

[0003] TRIM21 (Tripartite Motif-Containing 21) is a widely expressed cytoplasmic E3 ubiquitin ligase and Fc receptor. It is one of more than 80 members of the TRIM family in the human body. This protein plays an important role in the occurrence and development of inflammatory responses, cancer and autoimmune diseases. Among the many physiological and pathological processes involved, TRIM21 has attracted much research attention because it plays the role of the last line of defense against viral infection in cells. As an intracytoplasmic Fc receptor, TRIM21 can bind to the Fc segment of antibodies, mediate antibody-dependent intracellular neutralization (ADIN), and play an antiviral infection role. Studies have shown that not all antibodies have a neutralizing effect when binding to viruses. After being bound by non-neutralizing antibodies, viruses may still have the ability to infect cells. When these antibody-carrying viruses enter cells, they will be recognized by TRIM21 in the cytoplasm and trigger their self-ubiquitination, thereby inducing proteasome degradation of the virus. This process is called ADIN. In the process of mediating ADIN, the K63 ubiquitin chain formed by TRIM21 self-ubiquitination will be removed by the proteasome component protein deubiquitinase Poh1, which then activates the innate immune signaling pathway and induces interferon production, initiating the innate immune response to clear the virus infection. TRIM21 plays two important roles in these processes: immune effector (clearing viruses) and sensor (activating immune signal transduction).

[0004] Compared with the immunological research on TRIM21, there are few reports on the application of TRIM21 in the treatment of diseases such as tumors. Recent studies have found that the expression of TRIM21 is closely related to the occurrence and development of pancreatic cancer. Rosalyn B. Irby et al. analyzed the correlation between the expression of TRIM21 in tumor tissue samples of pancreatic cancer patients and the survival of patients. The results showed that patients with higher TRIM21 expression levels showed shorter overall survival and disease-free survival, while patients with low expression levels showed longer overall survival and disease-free survival. In addition, studies have found that TRIM21 plays two opposite roles in different types of cancer, either suppressing or promoting cancer, and it only plays a role in promoting cancer in limited types of cancer such as pancreatic cancer and brain glioma. That is, TRIM21 has a high specific correlation with the occurrence and development of pancreatic cancer. If the unique biological functions of TRIM21 can be fully utilized to form multiple effects on pancreatic tumors, it will be expected to enhance the anti-tumor effect of TRIM21 as a target.

[0005] TRIM21's unique immune effector function is based on the E3 ubiquitin ligase activity and Fc receptor properties, and can be used to degrade pancreatic cancer-related target proteins. The targeted protein degradation system Trim-Away, which has been developed in recent years, uses this function to induce the degradation of intracellular proteins using antibodies as protein degraders. Targeted protein degradation (TPD) is an emerging technology in the field of drug development in recent years. This technology uses functional molecules (degraders) to utilize the naturally existing protein degradation system (ubiquitin-proteasome system and autophagy-lysosome pathway) in cells to degrade disease-related proteins, thereby achieving the purpose of treating diseases. This type of technology uses a different mode of action from inhibiting protein function to directly induce the degradation of target proteins, thereby making many currently "undruggable" targets "druggable" and becoming actionable targets again. By designing degraders that simultaneously bind to E3 ubiquitin ligases and target proteins, the ubiquitin-proteasome system is used to degrade intracellular disease-related proteins, which is the fastest-growing and most promising system in TPD technology.

[0006] Another unique biological function that TRIM21 can utilize is its immune sensor function to activate antiviral immune responses. Studies on antiviral immune mechanisms have shown that when natural immune sensors in cells detect viral molecules, type I and type III interferons will be produced, which can induce cells to enter an antiviral state, thereby inhibiting viral replication. Interferon itself can act as an adjuvant to trigger a strong immune response, and ultimately lead to a cascade of cytokines. Inspired by this, in recent years, the field of anti-tumor immunotherapy has explored strategies to induce tumors to produce antiviral immune responses and treat cancer. These strategies use artificially synthesized induction molecules that simulate viral or bacterial infections to induce "pathogen-induced" natural immune responses in tumors to achieve therapeutic purposes. Summary of the invention

[0007] The purpose of the present invention is to provide a fusion protein degrader, which can simulate the "virus-host immune interaction" and be recognized by TRIM21 in diseased cells, thereby triggering the dual functions of TRIM21 as an immune effector and sensor, thereby inducing the simultaneous degradation of TRIM21 and disease-related target proteins, and activating the antiviral immune response of diseased tissues, exerting multiple therapeutic effects.

[0008] The first aspect of the present invention provides a fusion protein degrader, comprising a target protein-specific binding sequence, a linker and a TRIM21-specific binding sequence connected in sequence, wherein the target protein is a disease-related target protein, and the target protein-specific binding sequence is a protein sequence that specifically binds to the disease-related target protein; the disease-related target protein is a target protein associated with a disease in which TRIM21 is highly expressed.

[0009] The meaning of "TRIM21 high expression" in the present invention is well known to those skilled in the art, and refers to the expression of TRIM21 in the diseased tissue (such as tumor tissue) of patients with this type of disease (such as cancer) is higher than that in normal tissue, and its expression is sufficient to induce the degradation of disease-related target proteins, thereby inhibiting the progression of the disease. The higher expression of TRIM21 in diseased tissue compared to normal tissue can be a characteristic of the disease itself, or it can be achieved by artificial induction. For example, a DNA sequence encoding TRIM21 is introduced into the target cells of a certain disease, and is expressed only in cells with the disease through a specific promoter, degrading pathogenic proteins.

[0010] The disease with this feature is preferably cancer, including but not limited to pancreatic cancer or brain glioma, and the degradation agent of the present invention can inhibit the proliferation of tumor cells.

[0011] According to a preferred embodiment of the present invention, the TRIM21 specific binding sequence is the RING domain of TRIM21, and its sequence is shown in SEQ ID NO:1.

[0012] MASAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKG GGSVCPVCRQRFLLKNLRPNRQLANMVNNLKEISQEARE (SEQ ID NO: 1).

[0013] According to a preferred embodiment of the present invention, the cancer is pancreatic cancer, and the disease-related target protein is KRAS protein.

[0014] KRAS (Kirsten Rat Sarcoma Viral Oncogene Homologue) protein is a popular target for pancreatic cancer treatment and a suitable target protein for TRIM21-mediated targeted protein degradation. This protein is a small GTPase encoded by the KRAS gene and belongs to the RAS superprotein family. Studies have shown that more than 90% of pancreatic cancer patients have KRAS mutations, so KRAS mutant protein has become a very promising target for pancreatic cancer treatment. However, for more than 30 years, KRAS has been considered a "difficult to drug" target. Although covalent inhibitors targeting KRAS-G12C mutations have achieved gratifying results in patients with non-small cell lung cancer in recent years; however, for most pancreatic cancer patients carrying KRAS-G12D mutations, the drug has very limited effect, and new drugs or new strategies for pancreatic cancer treatment are urgently needed. TIRM21-mediated targeted protein degradation provides a potential solution strategy for directly targeting the difficult-to-drug KRAS.

[0015] Accordingly, the target protein specific binding sequence is a KRAS specific binding sequence, and the KRAS specific binding sequence is preferably as shown in SEQ ID NO:2.

[0016] AAAMDLGKKLLEAARAGQDDEVRILMANGADVNASDRWGWTPLHLAAWWGHLEIVEVLLKRGADVSAADLHGQSPLHLAAMVGHLEIVEVLLKYGADVNAKDTMGATPLHLAARSGHLEIVEELLKNGADMNAQDKFGKTTFDISTDNGNEDLAEILQKL (SEQ ID NO: 2).

[0017] Based on the same principle, when the cancer is glioma, glioma-related target proteins can also be selected.

[0018] According to a preferred embodiment of the present invention, the connector is a polypeptide chain, which serves to separate the elements before and after the connector without affecting the realization of their respective functions. For this purpose, the connector is usually a flexible chain, and may also be partially rigid or even completely rigid as required. Those skilled in the art may set the connector according to the structure of the element, and the present invention has no limitation on this. According to a specific embodiment of the present invention, the sequence of the connector is G m or (GGGGS) n , m and n are each independently any integer between 1 and 20, for example, any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or a value within the range of any two of the above values.

[0019] According to the present invention, preferably, the fusion protein degrader may also include a histidine tag, which is used for in vitro protein purification of the degrader on the one hand, and on the other hand, the degrader can utilize the proton sponge effect of the histidine tag to achieve endosomal escape in the cell. The histidine tag is arranged on the flank of the TRIM21-specific binding sequence or the target protein-specific binding sequence, that is, adjacent to the upstream or downstream. For example, when the target protein-specific binding sequence and the TRIM21-specific binding sequence are arranged from the N-terminus to the C-terminus, the histidine tag may be arranged on the upstream N-terminal side of the target protein-specific binding sequence, or on the downstream C-terminal side of the TRIM21-specific binding sequence, and vice versa. The sequence of the histidine tag is preferably as shown in SEQ ID NO: 3.

[0020] HHHHHH (SEQ ID NO: 3)

[0021] A polypeptide linker is preferably provided between the histidine tag and other elements (TRIM21-specific binding sequence or target protein-specific binding sequence), and the polypeptide linker can be G m or (GGGGS) n , m and n are each independently any integer between 1 and 20, for example, any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or a value within the range of any two of the above values.

[0022] According to a specific embodiment of the present invention, the sequence of the fusion protein degrader is shown as SEQ ID NO: 4 or SEQ ID NO: 5.

[0023] AAAMDLGKKLLEAARAGQDDEVRILMANGADVNASDRWGWTPLHLAAWWGHLEIVEVLLKRGADVSAADLHGQSPLHLAAMVGHLEIVEVLLKYGADVNAKDTMGATPLHLAARSGHLEIVEELLKN GADMNAQDKFGKTTFDISTDNGNEDLAEILQKLGGGGSSMASAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKGGGSVCPVCRQRFLLKNLRPNRQLANMVNNLKEISQEARE(SEQ ID NO:4)

[0024] HHHHHHGGGAAAMDLGKKLLEAARAGQDDEVRILMANGADVNASDRWGWTPLHLAAWWGHLEIVEVLLKRGADVSAADLHGQSPLHLAAMVGHLEIVEVLLKYGADVNAKDTMGATPLHLAARSGHLEIVE ELLKNGADMNAQDKFGKTTFDISTDNGNEDLAEILQKLGGGGSSMASAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKGGGSVCPVCRQRFLLKNLRPNRQLANMVNNLKEISQEARE(SEQ ID NO: 5).

[0025] The second aspect of the present invention provides a disease-related target protein degrader, comprising an intracellular delivery-promoting peptide and the above-mentioned fusion protein degrader; the intracellular delivery-promoting peptide is a functional polypeptide used to improve the stability of the degrader in vivo and / or promote the intracellular delivery of the degrader in diseased cells. The disease is, for example, cancer, and the diseased cells are, for example, tumor cells.

[0026] According to the present invention, the intracellular delivery promoting peptide includes but is not limited to at least one of a blood-brain barrier trans-peptide, a targeting peptide, an albumin binding domain, a histidine tag and a cell penetrating peptide (CPP). For pancreatic cancer cells, the targeting peptide is a pancreatic cancer targeting peptide. For glioma, a blood-brain barrier trans-peptide is preferably provided, and the targeting peptide used is correspondingly a glioma targeting peptide.

[0027] Specifically, the disease-related target protein degrader may contain the above-mentioned various types of promoting peptides at the same time, or may contain one, two or three of them, for example, a targeting peptide and an albumin binding domain, or a targeting peptide and a cell-penetrating peptide CPP, or an albumin binding domain and a cell-penetrating peptide CPP. When multiple peptides are included at the same time, the multiple peptides may be located upstream or downstream of the fusion protein degrader at the same time, or may be located upstream or downstream of the fusion protein degrader respectively. Preferably, when a targeting peptide is included, the targeting peptide is preferably located at the outermost side of the degrader, that is, at the N-terminus or C-terminus of the degrader, preferably at the N-terminus.

[0028] The sequence of the pancreatic cancer targeting peptide is preferably as shown in SEQ ID NO:6.

[0029] KTLLPTP (SEQ ID NO: 6).

[0030] The sequence of the albumin binding domain is preferably as shown in SEQ ID NO:7.

[0031] LPHSHRAHSLPP (SEQ ID NO: 7).

[0032] The sequence of the CPP is preferably as shown in SEQ ID NO:8.

[0033] VSRRRRRRGGRRRR (SEQ ID NO: 8).

[0034] According to the present invention, in order to ensure the realization of the functions of each element, a connector can be set between any two adjacent elements. In the present invention, the element refers to a polypeptide in the degradation agent that can independently realize a certain function, for example, a TRIM21-specific binding sequence, a target protein-specific binding sequence, a histidine tag, an intracellular delivery-promoting peptide (pancreatic cancer targeting peptide, albumin binding domain, cell-penetrating peptide CPP, etc.). The definition of the connector is as described above, and the sequence is preferably G m or (GGGGS) n , m and n can be any integer between 1 and 20.

[0035] Figure 1 The present invention shows the principle of a new strategy for treating pancreatic cancer by dual-targeted protein degradation and immune activation mediated by TRIM21 in a specific embodiment of the present invention, and demonstrates the functional mechanism of each of the above elements. This principle is also applicable to other diseases with high expression of TRIM21, such as brain glioma. The degradation agent will play the following roles in vivo (such as Figure 1As shown in the figure): When the degrader enters the circulatory system, it achieves long blood circulation by binding to albumin in the blood through the albumin binding domain, and achieves transvascular endothelial cell transport by transcytosis mediated by the albumin receptor gp60. Subsequently, under the action of the targeting peptide, it is enriched in the pancreatic tumor and taken up by pancreatic cancer cells through the receptor Plectin-1-mediated endocytosis pathway. At the same time, the degrader can also take advantage of the stronger macropinocytosis of KRAS mutant cells and the biological characteristics of low expression of FcRn receptors, and be taken up by pancreatic cancer cells through the macropinocytosis pathway, and then use the proton sponge effect of the histidine tag to achieve endosomal escape (such as introducing cell-penetrating peptides into the degrader, the degrader can also reach the cytoplasm with the help of the transcytosis, transmembrane and endosomal escape functions of the cell-penetrating peptide. This effect is not shown in the figure). Figure 1 ); in the cytoplasm, the degrader binds to the highly expressed TRIM21 in the cell through the RING domain, and binds to KRAS through the KRAS specific binding sequence to form a "TRIM21-degrader-KRAS" ternary complex; at the same time, the binding of the RING domain to TRIM21 further activates the self-ubiquitination of TRIM21 and the ubiquitination of the target protein, prompting the ternary complex to be recognized and degraded by the proteasome. While the dual degradation of TRIM21 and KRAS forms a dual-target effect on pancreatic cancer cells, the activation of TRIM21 will also open the downstream innate immune pathway, activate transcription factors such as NF-κB, AP-1, IRF3, IRF5 and IRF7, and initiate transcription, leading to the production of proinflammatory factors such as interferon, activating the tumor immunosuppressive microenvironment, and further enhancing the anti-tumor effect of the degrader.

[0036] In practical applications, those skilled in the art may set some or all of the components according to the above principles and in combination with specific needs.

[0037] For example, the sequence of the disease-associated target protein degrader can be selected from the following polypeptide sequences:

[0038] (1) N-terminus-C-terminus: histidine tag, linker, KRAS-specific binding sequence, linker, TRIM21 RING domain, linker and cell-penetrating peptide (eg, the sequence shown in SEQ ID NO: 9).

[0039] (2) N-terminus-C-terminus: histidine tag, linker, TRIM21 RING domain, linker, KRAS-specific binding sequence, linker and cell-penetrating peptide.

[0040] (3) N-terminus-C-terminus: TRIM21 RING domain, linker, KRAS-specific binding sequence, linker, cell-penetrating peptide, linker and histidine tag.

[0041] (4) N-terminus-C-terminus: KRAS-specific binding sequence, linker, TRIM21 RING domain, linker, cell-penetrating peptide, linker and histidine tag.

[0042] (5) N-terminus-C-terminus: albumin binding domain, linker, TRIM21 RING domain, linker, KRAS specific binding sequence, linker, cell penetrating peptide, linker and histidine tag.

[0043] (6) N-terminus-C-terminus: albumin binding domain, linker, KRAS specific binding sequence, linker, TRIM21 RING domain, linker, cell penetrating peptide, linker and histidine tag.

[0044] (7) N-terminus-C-terminus: TRIM21 RING domain, linker, KRAS-specific binding sequence, linker, albumin binding domain, linker, cell-penetrating peptide, linker and histidine tag.

[0045] (8) N-terminus-C-terminus: KRAS-specific binding sequence, linker, TRIM21 RING domain, linker, albumin binding domain, linker, cell-penetrating peptide, linker and histidine tag.

[0046] (9) N-terminus-C-terminus: histidine tag, linker, albumin binding domain, linker, TRIM21 RING domain, linker, KRAS specific binding sequence, linker and cell penetrating peptide.

[0047] (10) N-terminus-C-terminus: histidine tag, linker, albumin binding domain, linker, KRAS specific binding sequence, linker, TRIM21 RING domain, linker and cell penetrating peptide.

[0048] (11) N-terminus-C-terminus: histidine tag, linker, TRIM21 RING domain, linker, KRAS-specific binding sequence, linker, albumin binding domain, linker and cell-penetrating peptide.

[0049] (12) N-terminus-C-terminus: histidine tag, linker, KRAS-specific binding sequence, linker, TRIM21 RING domain, linker, albumin binding domain, linker and cell-penetrating peptide.

[0050] (13) N-terminus-C-terminus: pancreatic cancer targeting peptide, linker, albumin binding domain, linker, TRIM21 RING domain, linker, KRAS specific binding sequence, linker, cell penetrating peptide, linker and histidine tag.

[0051] (14) N-terminus-C-terminus: pancreatic cancer targeting peptide, linker, albumin binding domain, linker, KRAS specific binding sequence, linker, TRIM21 RING domain, linker, cell penetrating peptide, linker and histidine tag.

[0052] (15) N-terminus-C-terminus: pancreatic cancer targeting peptide, linker, TRIM21 RING domain, linker, KRAS specific binding sequence, linker, albumin binding domain, linker, cell penetrating peptide, linker and histidine tag.

[0053] (16) N-terminus-C-terminus: pancreatic cancer targeting peptide, linker, KRAS specific binding sequence, linker, TRIM21 RING domain, linker, albumin binding domain, linker, cell penetrating peptide, linker and histidine tag.

[0054] (17) N-terminus-C-terminus: albumin binding domain, linker, TRIM21 RING domain, linker, KRAS specific binding sequence, linker, cell penetrating peptide, linker, histidine tag, linker and pancreatic cancer targeting peptide.

[0055] (18) N-terminus-C-terminus: albumin binding domain, linker, KRAS specific binding sequence, linker, TRIM21 RING domain, linker, cell penetrating peptide, linker, histidine tag, linker and pancreatic cancer targeting peptide.

[0056] (19) N-terminus-C-terminus: RING domain of TRIM21, linker, KRAS-specific binding sequence, linker, albumin binding domain, linker, cell penetrating peptide, linker, histidine tag, linker and pancreatic cancer targeting peptide.

[0057] (20) N-terminus-C-terminus: KRAS-specific binding sequence, linker, TRIM21 RING domain, linker, albumin binding domain, linker, cell penetrating peptide, linker, histidine tag, linker and pancreatic cancer targeting peptide.

[0058] (21) N-terminus-C-terminus: histidine tag, linker, albumin binding domain, linker, TRIM21 RING domain, linker, KRAS specific binding sequence, linker, cell penetrating peptide, linker and pancreatic cancer targeting peptide.

[0059] (22) N-terminus-C-terminus: histidine tag, linker, albumin binding domain, linker, KRAS specific binding sequence, linker, TRIM21 RING domain, linker, cell penetrating peptide, linker and pancreatic cancer targeting peptide.

[0060] (23) N-terminus-C-terminus: histidine tag, linker, TRIM21 RING domain, linker, KRAS-specific binding sequence, linker, albumin binding domain, linker, cell-penetrating peptide, linker, and pancreatic cancer targeting peptide.

[0061] (24) N-terminus-C-terminus: histidine tag, linker, KRAS-specific binding sequence, linker, TRIM21 RING domain, linker, albumin binding domain, linker, cell penetrating peptide, linker, and pancreatic cancer targeting peptide.

[0062] The third aspect of the present invention provides a DNA encoding the above-mentioned degrader, including both DNA encoding a fusion protein degrader and DNA encoding a disease-related target protein degrader.

[0063] The fourth aspect of the present invention provides an mRNA encoding the above-mentioned degrader, including both mRNA encoding a fusion protein degrader and mRNA encoding a disease-related target protein degrader.

[0064] The fifth aspect of the present invention provides the use of the above-mentioned degradation agent, the above-mentioned DNA or the above-mentioned mRNA in the preparation of a drug, wherein the drug is used to treat a disease with high expression of TRIM21, wherein the disease is preferably cancer, and the cancer includes but is not limited to pancreatic cancer or brain glioma.

[0065] The degradation agent of the present invention has the characteristics of both clearing viruses (immune effector) and activating immune signal transduction (immune sensor). By activating TRIM21, it simulates the "virus-host immune interaction", induces the dual degradation of disease-related target proteins and TRIM21, and activates the natural immune signaling pathway mediated by TRIM21, inducing the antiviral immune response of diseased tissues, thereby enhancing the therapeutic effect of the degradation agent.

[0066] Other features and advantages of the present invention will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] The above and other objects, features and advantages of the present invention will become more apparent through a more detailed description of exemplary embodiments of the present invention with reference to the accompanying drawings.

[0068] Figure 1 This is a schematic diagram of a new strategy for treating pancreatic cancer by dual-targeted protein degradation and immune activation mediated by TRIM21 in a specific embodiment of the present invention.

[0069] Figure 2 The figure shows the expression levels of TRIM21 and KRAS in pancreatic cancer cells detected by Western Blot.

[0070] Figure 3 Degraders are shown to induce dual degradation of TRIM21 and KRAS.

[0071] Figure 4 The purification results of the degrader are shown, including SDS-PAGE (left) and Western Blot (right) of the degrader, Lane M: protein marker, Lane 1: BSA, Lane 2: degrader; Western Blot was detected with anti-His antibody.

[0072] Figure 5 The purification results of the control protein of the degrader are shown, SDS-PAGE (left) and Western Blot (right) of the control protein of the degrader, Lane M: protein marker, Lane 1: BSA, Lane 2: control protein of the degrader; Western Blot was detected with anti-His antibody.

[0073] Figure 6 The inhibitory effect of the degraders on the proliferation of pancreatic cancer cells is shown.

[0074] Figure 7 The inhibitory effect of the control protein of the degrader on the proliferation of pancreatic cancer cells is shown. DETAILED DESCRIPTION

[0075] The preferred embodiments of the present invention will be described in more detail below. Although the preferred embodiments of the present invention are described below, it should be understood that the present invention can be implemented in various forms and should not be limited to the embodiments set forth herein.

[0076] The biomimetic degradation agent constructed in the embodiment of the present invention is designed for two pancreatic cancer-related target proteins, TRIM21 and KRAS, and can simultaneously induce the degradation of the two target proteins to form a dual-target effect on pancreatic cancer cells. Therefore, the expression levels of these two proteins in the commonly used pancreatic cancer cells PANC-1 and MIAPaCa-2 were first detected. Western Blot results showed that TRIM21 and KRAS were well expressed in pancreatic cancer cells PANC-1 and MIAPaCa-2 ( Figure 2 ). Since MIAPaCa-2 is a KRAS dependent cell line, the present invention mainly selects this cell line for research.

[0077] Example 1 Verification of the dual-target degradation function of the core component of the degradation agent

[0078] The components of the degrader can be roughly divided into two categories: the core part that plays the role of inducing dual-target protein degradation and immune activation (TRIM21-specific binding sequence RING domain and KRAS-specific binding sequence DP KRAS) and the various modules introduced to solve the problem of in vivo delivery of degraders (histidine tags, pancreatic cancer targeting peptides, albumin binding domains, and cell-penetrating peptides, etc.). The embodiment of the present invention first investigated the effects of the two core components of the degrader (RING domain and DP KRAS) on the function of the degrader. In view of the fact that the dual-target degradation function of the degrader is the basis of the immune activation function, the experiment was first conducted with the dual-target protein degradation efficiency as an indicator.

[0079] In this example, the DP KRAS and RING domains were connected by a linker (GGGGS) (sequence is SEQ ID NO: 4), and the plasmid of the degrader DP KRAS-RING was constructed and transfected into pancreatic cancer cells MIA PaCa-2 for expression under the induction of DOX. Western Blot results showed that the core component of the degrader can induce the dual degradation of TRIM21 and KRAS ( Figure 3 ).

[0080] Example 2 Expression and purification of degradation agent and control protein in E. coli system

[0081] The present invention adds a module introduced to solve the problem of in vivo delivery to the core component sequence of the degrader, constructs the degrader HDRC (His-DP KRAS-RING-CPP), and expresses it in vitro in large quantities through the E. coli expression system. A control protein (HDRC-Ctl) is then set to verify the feasibility of introducing the degrader into cells in the form of protein to induce dual degradation of KRAS and TRIM21 in pancreatic cancer cells. The key sites involved in binding to KRAS in the control protein have mutated, so it cannot bind to KRAS. According to the design, it can only induce the degradation of TRIM21.

[0082] The degrader comprises: a histidine tag, a linker GGG, a KRAS specific binding sequence, a linker GGGGS, a RING domain of TRIM21, a linker GGGGS and a cell-penetrating peptide, and the sequence is shown in SEQ ID NO:9.

[0083] HHHHHHGGGAAAMDLGKKLLEAARAGQDDEVRILMANGADVNASDRWGWTPLHLAAWWGHLEIVEVLLKRGADVSAADLHGQSPLHLAAMVGHLEIVEVLLKYGADVNAKDTMGATPLHLAARSGHLEIVEELLKNGADMN AQDKFGKTTFDISTDNGNEDLAEILQKLGGGGSSAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKGGGSVCPVCRQRFLLKNLRPNRQLANMVNNLKEISQEAREGGGGSVSRRRRRRGGRRRR(SEQ ID NO: 9).

[0084] A control protein (HDRC-Ctl) was designed, in which the KRAS-specific binding sequence involved in the key site for binding to KRAS (amino acids marked in bold and underlined) had been mutated (SEQ ID NO: 9), thereby substantially losing the ability to bind to KRAS, and the rest of the sequence was the same as the degrader HDRC.

[0085] AAAMDLGKKLLEAARAGQDDEVRILMANGADVNASDR G G G TPLHLAA AG GHLEIVEVLLKRGADVSAADLHGQSPLHLAAMVGHLEIVEVLLKYGADVNAKDTMGATPLHLAARSGHLEIVEELLKNGADMNAQDKFGKTTFDISTDNGNEDLAEILQKL(SEQ ID NO: 9)

[0086] The steps of constructing plasmid and expressing are as follows: connect the DNA sequence encoding the degradation agent or control protein into the pET30a vector to construct the degradation agent expression plasmid, and then transfer it to Escherichia coli BL21 (DE3) for induced expression. The expression conditions are: 15°C induction for 16h, IPTG concentration is 0.2mM.

[0087] Affinity purification was performed using a nickel column. The components of the solutions used in each step of the purification were:

[0088]

[0089] The purified protein was desalted and stored in PBS.

[0090] The characterization results of the purified degradation agent are as follows Figure 4 shown. Figure 4The left picture is the SDS-PAGE of the degrader, and the right picture is the Western Blot of the degrader, Lane M: protein marker, Lane 1: BSA, Lane 2: degrader; Western Blot was detected with anti-His antibody. The expression and purification effect of the target protein were confirmed by SDS-PAGE.

[0091] The characterization results of the purified control protein are shown in Figure 5 shown. Figure 5 The left picture is the SDS-PAGE of the control protein, and the right picture is the Western Blot of the control protein. Lane M: protein marker, Lane 1: BSA, Lane 2: control protein of the degradation agent; Western Blot was detected with anti-His antibody. The expression and purification effect of the control protein were confirmed by SDS-PAGE.

[0092] Test Example 1 Inhibitory Effects of Degraders and Control Proteins on Pancreatic Cancer Cell Proliferation

[0093] The inhibitory effects of the degradation agent HDRC and its control protein HDRC-Ctl on the proliferation of pancreatic cancer cells MIA PaCa-2 were determined by CCK8 cytotoxicity assay. Figure 6 and Figure 7 The results showed that the degradation agent and its control protein had a significant inhibitory effect on the proliferation of pancreatic cancer cells after 48 hours of action, and the degradation agent (IC 50 =0.52 μM) showed a significant difference compared to the control protein (IC 50 =2.34 μM) had a more obvious proliferation inhibition effect.

[0094] The above results show that both the degrader and its control protein can inhibit the proliferation of pancreatic cancer cells by inducing the degradation of the target protein, but the inhibitory effect of the degrader is more obvious. The reason is that although the control protein lacks the ability to bind to KRAS, the RING domain contained in it activates TRIM21 by binding to TRIM21 in pancreatic cancer cells, and triggers its self-ubiquitination, thereby inducing the degradation of TRIM21 by the proteasome, and the degradation of TRIM21 ultimately affects the proliferation of pancreatic cancer cells, so it also has a certain effect of inhibiting the proliferation of pancreatic cancer cells. In contrast, the degrader can bind to KRAS and TRIM21 in the cell, thereby activating TRIM21, triggering its self-ubiquitination and ubiquitination of KRAS, and then inducing the proteasome to double-degrade KRAS and TRIM21, thus showing a stronger cell proliferation inhibitory effect than the control protein. By setting the control protein, it is proved that the degrader of the present invention can induce the dual degradation of pancreatic cancer-related target proteins KRAS and TRIM21, and achieve an enhanced anti-tumor effect.

[0095] It can be seen that the present invention utilizes the specific correlation between TRIM21 and pancreatic cancer, and its characteristics of having both the functions of clearing viruses and activating immune signal transduction, to construct a degrader that can activate TRIM21, simulate the "virus-host immune interaction", induce the dual degradation of pancreatic cancer-related target proteins KRAS and TRIM21, and activate the natural immune signaling pathway mediated by TRIM21, thereby inducing the antiviral immune response of the tumor and enhancing the anti-tumor effect of the degrader.

[0096] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and changes will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments.

Claims

1. A fusion protein degrader, comprising a target protein-specific binding sequence, a linker and a TRIM21-specific binding sequence connected in sequence, wherein the target protein-specific binding sequence is a protein sequence that specifically binds to a disease-related target protein; and the disease-related target protein is a target protein associated with a disease in which TRIM21 is highly expressed.

2. The fusion protein degradation agent according to claim 1, wherein The TRIM21-specific binding sequence is the RING domain of TRIM21, and its sequence is shown in SEQ ID NO: 1; The disease is cancer, preferably pancreatic cancer or brain glioma; More preferably, the cancer is pancreatic cancer, the disease-related target protein is KRAS protein, the target protein-specific binding sequence is a KRAS-specific binding sequence, and the KRAS-specific binding sequence is preferably as shown in SEQ ID NO: 2; The linker is a polypeptide chain, and its sequence is preferably G m or (GGGGS) n , m and n are each independently an integer of 1-20.

3. The fusion protein degradation agent according to claim 1, wherein It also includes a histidine tag, which is disposed on the flank of the TRIM21-specific binding sequence or the target protein-specific binding sequence, and the sequence of the histidine tag is preferably as shown in SEQ ID NO: 3; A polypeptide linker is optionally provided between the histidine tag and the TRIM21 specific binding sequence or the target protein specific binding sequence, and the sequence of the polypeptide linker is preferably G m or (GGGGS) n , m and n are each independently an integer of 1-20.

4. The fusion protein degradation agent according to claim 3, wherein The sequence of the fusion protein degrading agent is shown in SEQ ID NO: 4 or SEQ ID NO:

5.

5. A disease-related target protein degrader, comprising an intracellular delivery-promoting peptide and the fusion protein degrader according to any one of claims 1 to 4; the intracellular delivery-promoting peptide is a functional polypeptide used to improve the stability of the degrader in vivo and / or promote the intracellular delivery of the degrader in diseased cells.

6. The degradation agent according to claim 5, wherein The intracellular delivery promoting peptide is at least one of a blood-brain barrier-spanning polypeptide, a targeting peptide, an albumin binding domain, a histidine tag and a cell-penetrating peptide; the targeting peptide is preferably a pancreatic cancer targeting peptide.

7. The degradation agent according to claim 6, wherein The sequence of the pancreatic cancer targeting peptide is shown in SEQ ID NO: 6; the sequence of the albumin binding domain is shown in SEQ ID NO: 7; and the sequence of the cell penetrating peptide CPP is shown in SEQ ID NO: 8; The pancreatic cancer targeting peptide is located at the N-terminus or C-terminus of the degrader, preferably at the N-terminus; A linker is provided between two adjacent elements in the degradation agent, and the sequence of the linker is preferably G m or (GGGGS) n , m and n are each independently an integer of 1-20.

8. The degradation agent according to claim 7, wherein The sequence of the disease-related target protein degrader is shown in SEQ ID NO:

9.

9. A DNA or mRNA encoding the degradation agent according to any one of claims 1 to 8.

10. Use of the degrading agent according to any one of claims 1 to 8 and the DNA or mRNA according to claim 9 in the preparation of a drug, wherein the drug is used to treat a disease with high expression of TRIM21, wherein the disease is preferably cancer, more preferably pancreatic cancer or brain glioma.

Citation Information

Cited By

  • Chimera for degrading CARD structural domain protein aggregate and application of chimera

    CN121574267A

  • Chimeras degrading card domain protein aggregates and uses thereof

    CN121574267B

  • Fusion protein for targeted degradation of stress particles and application thereof

    CN122103377A

  • Nucleic acid molecule targeting SARS-CoV-2 virus Spike protein, recombinant expression vector containing nucleic acid molecule and application

    CN122146697A